Showing 2620 results
- https://www.novartis.com/news/media-releases/real-world-data-show-novartis-drug-revolade-improves-outcomes-itp-patients-compared-other-second-line-therapiesRevolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
- https://www.novartis.com/news/media-releases/novartis-announces-longer-term-analyses-from-pivotal-kymriah-trials-showed-durable-responses-are-maintained-patients-advanced-blood-cancersIn the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration…
- https://www.novartis.com/news/media-releases/novartis-announces-new-crizanlizumab-seg101-data-analysis-sickle-cell-disease-and-investment-sentry-clinical-programNew post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patientsCrizanlizumab, a monthly infusion…
- https://www.novartis.com/news/media-releases/novartis-announces-eu-approval-gilenya-children-and-adolescents-ms-making-it-first-and-only-oral-disease-modifying-treatment-these-patients-europeApproval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free at…
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
https://www.novartis.com/news/media-releases/sandoz-receives-eighth-european-commission-approval-biosimilar-ziextenzo-pegfilgrastimBiosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated to…- https://www.novartis.com/news/media-releases/alcon-highlight-its-vision-strategy-and-benefits-standalone-company-investors-and-analysts-new-york-and-londonAlcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and…
- https://www.novartis.com/news/media-releases/novartis-announces-landmark-eu-approval-one-time-gene-therapy-luxturna-restore-vision-people-rare-inherited-retinal-diseaseLuxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65…
- https://www.novartis.com/news/violence-against-innocent-people-runs-counter-our-work-improve-human-health
- https://www.novartis.com/news/media-releases/novartis-rises-second-place-2018-access-medicine-indexCompany leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in 2016…
- https://www.novartis.com/news/media-releases/sandoz-and-pear-therapeutics-announce-launch-reset-treatment-patients-substance-use-disorderreSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…